{"title": "Microdosing Psilocybin Triggers Incremental mTOR‑Dependent Synaptogenesis in mPFC, Gradually Dampening Amygdala Threat Reactivity in PTSD", "body": "# Hypothesis\nRepeated low‑dose (microdose) psilocybin administration produces a cumulative increase in medial prefrontal cortex (mPFC) dendritic spine density via repeated, sub‑threshold activation of the 5‑HT2A‑mTOR signaling cascade. This progressive synaptic remodeling reduces amygdala‑driven threat reactivity over weeks, yielding measurable PTSD symptom improvement without the acute perceptual effects of full doses.\n\n## Rationale\n- Psilocybin is a potent 5‑HT2A agonist that acutely activates the mTOR pathway, driving rapid synthesis of plasticity‑related proteins (c‑Fos, BDNF, FosB, Junb) and increasing dendritic spine density in hippocampus and mPFC [2, 3].\n- Chronic SSRIs increase neuroplasticity slowly through sustained serotonin elevation, whereas psilocybin delivers intermittent, receptor‑direct bursts that may favor translational control of synaptic proteins via mTOR‑dependent mechanisms.\n- Preclinical work shows a single dose raises spine density for at least one month [3]; repeated sub‑psychedelic doses could summate this effect without triggering hallucinogenic thresholds.\n- PTSD is characterized by mPFC hypoactivity and amygdala hyperreactivity; enhancing mPFC synaptic capacity should improve top‑down inhibition of fear circuits.\n\n## Novel Mechanistic Insight\nWe propose that each microdose triggers a transient 5‑HT2A‑mediated rise in intracellular Ca2+, activating phospholipase C and subsequently the PI3K‑Akt‑mTOR cascade. Because the dose is below the threshold for robust cortical desynchronization, the downstream effect is a modest increase in translation of synaptic scaffolding proteins (e.g., PSD‑95, Synapsin‑I). Over multiple administrations, these incremental translation events surpass protein degradation rates, leading to a net gain in spine density. Concurrently, elevated BDNF release activates TrkB receptors, further sustaining mTOR signaling through a positive feedback loop. This synaptic strengthening enhances mPFC glutamatergic output to intercalated cells of the amygdala, increasing GABAergic inhibition of the central nucleus and lowering threat‑related firing.\n\n## Testable Predictions\n1. Biomarker trajectory – Serum BDNF and phosphorylated‑S6 (a downstream mTOR readout) will show a stepwise increase after each microdose, peaking 2–4 h post‑dose and returning toward baseline before the next dose, with a cumulative upward trend over 4 weeks.\n2. Electrophysiological signature – Resting‑state EEG will exhibit a gradual increase in frontal theta power and a decrease in amygdala‑derived high‑gamma (60‑90 Hz) coherence during threat‑cue tasks, correlating with spine density changes.\n3. Behavioral outcome – PCL‑5 scores will decline linearly with the estimated cumulative spine density gain, observable after 2–3 weeks of dosing, despite sub‑psychedelic subjective ratings.\n4. Specificity – Blocking mTOR with rapamycin administered prior to each microdose will abolish the biomarker and behavioral improvements, confirming pathway dependence.\n\n## Experimental Design (Outline)\n- Participants: 30 adults with clinically confirmed PTSD (CAPS‑5 ≥ 35), randomized 1:1 to microdose psilocybin (1 mg, orally, every third day for 4 weeks) or placebo.\n- Dosing: Microdose chosen based on pilot data showing plasma psilocybin ~5 ng/mL, well below the 20 ng/mL threshold for perceptual alterations.\n- Measurements:<br> • Serum BDNF and p‑S6 via ELISA/Western blot at 0 h, 2 h, 6 h post‑dose on days 1, 8, 15, 22.<br> • Resting‑state EEG and threat‑cue fMRI at baseline and weekly.<br> • CAPS‑5 and PCL‑5 at baseline, week 2, week 4, and 4‑week follow‑up.\n- Intervention arm: Subset (n=10) receives oral rapamycin (2 mg) 30 min before each microdose to test mTOR dependence.\n- Analysis: Mixed‑effects models for biomarker trajectories; mediation analysis testing whether change in p‑S6 predicts change in frontal theta, which in turn predicts PCL‑5 reduction.\n\n## Falsifiability\nIf microdosing fails to produce a detectable, dose‑dependent increase in serum p‑S6 or BDNF, or if EEG/fMRI markers of mPFC‑amygdala connectivity do not improve despite clinical symptom change, the hypothesis that incremental mTOR‑driven synaptogenesis underlies the therapeutic effect would be refuted. Similarly, if rapamycin does not block biomarker and symptom improvements, the proposed mechanistic pathway is invalid."}